奥洛他定联合匹多莫德治疗慢性荨麻疹的疗效及对外周血淋巴细胞亚群影响(1)
摘 要：目的 觀察奥洛他定联合匹多莫德口服对慢性荨麻疹患者临床疗效及外周血淋巴细胞亚群影响。方法 选择我院皮肤科门诊2018年1月～7月收治的56例慢性荨麻疹患者，按随机数表法均为A组和B组，各28例。A组单用奥洛他定治疗，B组采取奥洛他定联合匹多莫德治疗，另设健康对照组20例，治疗4周后比较A、B两组患者临床疗效，三组外周血T、B、NK淋巴细胞比例变化及不良反应发生率。结果 A组治疗总效率为57.14%，低于B组的92.85%，差异有统计学意义(P<0.05);A组治疗前后比较：CD3+、CD3+CD4+、CD19+、CD16+56+水平变化无统计学意义(P>0.05);CD3+CD8+增高、CD3+CD4+/CD3+CD8+降低，差异有统计学意义(P<0.05);B组治疗前后比较：CD3+、CD19+水平变化无统计学意义(P>0.05)，CD3+CD8+增高，CD3+CD4+、CD3+CD4+/CD3+CD8+、CD16+56+降低，差异有统计学意义(P<0.05);治疗后，两组患者CD19+水平变化无统计学意义(P>0.05)，A组患者CD3+、CD3+CD8+水平低于B组，CD3+CD4+、CD3+CD4+/CD3+CD8+、CD16+56+水平高于B组，差异有统计学意义(P<0.05);治疗过程中A组1例患者出现嗜睡、B组出现2例，均可耐受。结论 奥洛他定联合匹多莫德能有效治疗慢性荨麻疹，改善患者外周血淋巴细胞亚群水平，提高患者自身免疫力，安全有效。
, http://www.100md.com
关键词：奥洛他定;匹多莫德;慢性荨麻疹;淋巴细胞亚群
中图分类号：R758.24 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.21.041
文章编号：1006-1959(2018)21-0144-03
Efficacy of Olopatadine Combined with Pidotimod in the Treatment of Chronic Urticaria and Its Effect on Peripheral Blood Lymphocyte Subsets
GAN Hong-wan1，XIAO De-jun2，ZENG Yu1，YANG Ping1，ZHONG Yu1
, 百拇医药
(Department of Dermatology1，Department of Laboratory2，Ganzhou People's Hospital，Ganzhou 341000， Jiangxi，China)
Abstract：Objective To observe the clinical effect of Olopatadine combined with Pidotimod on chronic urticaria and the effect of peripheral blood lymphocyte subsets.Methods 56 patients with chronic urticaria were selected from January to July 2018 in our the department of dermatology of our hospital. According to the random number method， 28 cases in group A and 28 cases in group B were selected.Group A was treated with Olopatadine alone， group B with Olopatadine combined with Pidotimod， and control group with 20 healthy person.After 4 weeks of treatment， the clinical efficacy were compared among A and B， T， B， NK lymphocyte ratio and adverse reactions in three groups were compared.Results The total therapeutic efficiency in group A was 57.14%， which was lower than that in group B 92.85%，the difference was statistically significant(P<0.05).Before and after treatment， the levels of CD3+，CD3+CD4+，CD19+，CD16+56+ were not significantly changed in group A(P>0.05).CD3+CD8+ increased and CD3+CD4+/CD3+CD8+ decreased，the difference was statistically significant (P<0.05).In group B， there was no significant difference in CD3+ and CD19+ levels before and after treatment(P>0.05)，CD3+CD8+ increased， CD3+CD4+，CD3+CD4+/CD3+CD8+，CD16+56+ significantly decreased，the difference was statistically significant(P<0.05).After treatment， there was no significant difference in the level of CD19+ between the two groups(P>0.05). The levels of CD3+ and CD3+ CD8+ were lower in group B than in group A.The levels of CD3+CD4+，CD3+CD4+/CD3+CD8+，CD16+56+ were significantly higher than those in group B，the difference was statistically significant(P<0.05).During the course of treatment， 1 patient in group A developed somnolence and 2 in group B， which could be tolerated.Conclusion Olopatadine combined with Pidotimod can effectively treat chronic urticaria， improve the level of lymphocyte subsets in peripheral blood of patients， improve the patients' own immunity， and be safe and effective., http://www.100md.com(甘红婉 肖德俊 曾 瑜 杨 萍 钟 雨)
, http://www.100md.com
关键词：奥洛他定;匹多莫德;慢性荨麻疹;淋巴细胞亚群
中图分类号：R758.24 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.21.041
文章编号：1006-1959(2018)21-0144-03
Efficacy of Olopatadine Combined with Pidotimod in the Treatment of Chronic Urticaria and Its Effect on Peripheral Blood Lymphocyte Subsets
GAN Hong-wan1，XIAO De-jun2，ZENG Yu1，YANG Ping1，ZHONG Yu1
, 百拇医药
(Department of Dermatology1，Department of Laboratory2，Ganzhou People's Hospital，Ganzhou 341000， Jiangxi，China)
Abstract：Objective To observe the clinical effect of Olopatadine combined with Pidotimod on chronic urticaria and the effect of peripheral blood lymphocyte subsets.Methods 56 patients with chronic urticaria were selected from January to July 2018 in our the department of dermatology of our hospital. According to the random number method， 28 cases in group A and 28 cases in group B were selected.Group A was treated with Olopatadine alone， group B with Olopatadine combined with Pidotimod， and control group with 20 healthy person.After 4 weeks of treatment， the clinical efficacy were compared among A and B， T， B， NK lymphocyte ratio and adverse reactions in three groups were compared.Results The total therapeutic efficiency in group A was 57.14%， which was lower than that in group B 92.85%，the difference was statistically significant(P<0.05).Before and after treatment， the levels of CD3+，CD3+CD4+，CD19+，CD16+56+ were not significantly changed in group A(P>0.05).CD3+CD8+ increased and CD3+CD4+/CD3+CD8+ decreased，the difference was statistically significant (P<0.05).In group B， there was no significant difference in CD3+ and CD19+ levels before and after treatment(P>0.05)，CD3+CD8+ increased， CD3+CD4+，CD3+CD4+/CD3+CD8+，CD16+56+ significantly decreased，the difference was statistically significant(P<0.05).After treatment， there was no significant difference in the level of CD19+ between the two groups(P>0.05). The levels of CD3+ and CD3+ CD8+ were lower in group B than in group A.The levels of CD3+CD4+，CD3+CD4+/CD3+CD8+，CD16+56+ were significantly higher than those in group B，the difference was statistically significant(P<0.05).During the course of treatment， 1 patient in group A developed somnolence and 2 in group B， which could be tolerated.Conclusion Olopatadine combined with Pidotimod can effectively treat chronic urticaria， improve the level of lymphocyte subsets in peripheral blood of patients， improve the patients' own immunity， and be safe and effective., http://www.100md.com(甘红婉 肖德俊 曾 瑜 杨 萍 钟 雨)